To report the efficacy and safety of LB2102, a DLL3-targeted CAR-T therapy, in a patient with recurrent extensive-stage small-cell lung cancer (ES-SCLC).
Approach:
Patient Background: A 51-year-old female with ES-SCLC received LB2102 off-label after ineligibility for a clinical trial.
Treatment Administration: The patient underwent lymphodepletion and received a single infusion of LB2102 (2.0 x 10^6 CAR-T cells/kg).
Monitoring and Evaluation: Post-infusion, the patient was monitored for adverse effects and tumor response through imaging and laboratory tests.
Key Findings:
The patient showed a 35% reduction in target lesions by week 12, consistent with partial response per RECIST 1.1 criteria, and a 100% reduction after one year.
No dose-limiting toxicity, cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity (ICANS) were observed.
The patient maintained an ECOG performance status of 1 and did not require further cancer treatment after one year.
Interpretation:
Limitations:
This is a single case study, limiting generalizability.
Long-term efficacy and safety data are not yet available from ongoing trials.
Conclusion:
The investigational therapy LB2102 demonstrated promising efficacy and safety in this patient with recurrent ES-SCLC.
by Chelsey M. Williams, Susanne M. Arnold, John L. Villano, Erika N. Amarilla Alonso, Christine F. Brainson, Paul O. Schwarzenberger, Sahista Vahora, Ayman Qasrawi, Reinhold Munker, B. Mark Evers, Zhonglin Hao
